Article
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2016
Zheng Hong, Zhao Weipeng, Yan Cihui, Watson Crystina C, Massengill Michael, Xie Mengyu, Massengill Chris, Noyes David R, Martinez Gary V, Afzal Roha, Chen Zhihua, Ren Xiubao, Antonia Scott J, Haura Eric B, Ruffell Brian, Beg Amer A
Abstract excerpt
PURPOSE: A significant limitation of checkpoint blockade immunotherapy is the relatively low response rate (e.g., ∼20% with PD-1 blockade in lung cancer). In this study, we tested whether strategies that increase T-cell infiltration to tumors can be efficacious in enhancing immunotherapy response. EXPERIMENTAL DESIGN: We performed an unbiased screen to identify FDA-approved oncology agents with an ability to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.